Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
This study is ongoing, but not recruiting participants.
Study NCT00390234 Information provided by National Cancer Institute (NCI)
First Received on October 18, 2006. Last Updated on May 7, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fallopian Tube Cancer
Female Reproductive Cancer
Ovarian Carcinosarcoma
Ovarian Sarcoma
Recurrent Ovarian Epithelial Cancer
Recurrent Uterine Sarcoma
Stage III Ovarian Epithelial Cancer
Stage III Uterine Sarcoma
Stage IV Ovarian Epithelial Cancer
Stage IV Uterine Sarcoma
Uterine Carcinosarcoma
Uterine Leiomyosarcoma
Additional conditions recognized in this trial
Carcinosarcoma
Fallopian Tube Neoplasms
Leiomyosarcoma
Mixed Tumor, Mullerian
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Sarcoma
Uterine Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Ovarian Diseases
Urogenital Neoplasms
Uterine Diseases
Interventions listed in this trial
ziv-aflibercept
laboratory biomarker analysis
pharmacological study
Additional drug interventions recognized in this trial
Endothelial Growth Factors
More general drug interventions related to this trial
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
